Compare · MRNA vs TECX
MRNA vs TECX
Side-by-side comparison of Moderna Inc. (MRNA) and Tectonic Therapeutic Inc. (TECX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRNA and TECX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $94.42B, about 226.8x TECX ($416.4M).
- MRNA has been more active in the news (11 items in the past 4 weeks vs 8 for TECX).
- MRNA has more recent analyst coverage (25 ratings vs 12 for TECX).
- Company
- Moderna Inc.
- Tectonic Therapeutic Inc.
- Price
- -
- -
- Market cap
- $94.42B
- $416.4M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2018
- News (4w)
- 11
- 8
- Recent ratings
- 25
- 12
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest MRNA
- SEC Form 4 filed by Moderna Inc.
- AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test
- Moderna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026
- SEC Form 4 filed by Moderna Inc.
- 2026 Takes a Promising Turn in the Fight Against Cancer as Five Advances Offer New Hope
- SEC Form 3 filed by Moderna Inc.
- Moderna, Inc. to Join the Nasdaq-100 Index® Beginning October 9, 2026
- Moderna downgraded by Citigroup with a new price target
- Moderna Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Moderna Adds Chief Operating Officer Role as Company Expands into Oncology
Latest TECX
- UBS initiated coverage on Tectonic Therapeutic with a new price target
- Chief Financial Officer Lochner Daniel covered exercise/tax liability with 520 shares, decreasing direct ownership by 0.89% to 58,024 units (SEC Form 4) to cover taxes
- Chief Scientific Officer Mcnamara Peter covered exercise/tax liability with 444 shares and sold $12,349 worth of shares (536 units at $23.04) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 54,305 units (SEC Form 4) to cover withholding tax
- Chief Medical Officer Ruddy Marcella K. covered exercise/tax liability with 525 shares, decreasing direct ownership by 0.78% to 67,157 units (SEC Form 4) to satisfy withholding tax
- Chief Executive Officer Reicin Alise covered exercise/tax liability with 1,545 shares, decreasing direct ownership by 0.50% to 309,078 units (SEC Form 4) (for withholding tax)
- Chief Business Officer Schwabish Marc covered exercise/tax liability with 411 shares, decreasing direct ownership by 0.91% to 44,903 units (SEC Form 4) (withholding obligation)
- SEC Form 8-K filed by Tectonic Therapeutic Inc.
- Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)
- SEC Form 4 filed by Chief Executive Officer Reicin Alise
- SEC Form 4 filed by Chief Medical Officer Ruddy Marcella K.